Rongyu Y. Zang-Yu Zang

180 Fenglin Road
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Retraction: Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis.

Retraction: Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis.

Journal: Oncotarget

Published: April 24, 2026

Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial.

Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial.

Journal: Journal of ovarian research

Published: February 10, 2026

S100A4 characterize antigen-presenting cancer-associated fibroblasts and predicts surgical outcomes in relapsed ovarian cancer.

S100A4 characterize antigen-presenting cancer-associated fibroblasts and predicts surgical outcomes in relapsed ovarian cancer.

Journal: Therapeutic advances in medical oncology

Published: October 30, 2025

Single-Cell Analysis Links C7+ Cancer-Associated Fibroblasts with Incomplete Resection in Platinum-Sensitive Relapsed Ovarian Cancer.

Single-Cell Analysis Links C7+ Cancer-Associated Fibroblasts with Incomplete Resection in Platinum-Sensitive Relapsed Ovarian Cancer.

Journal: Biomedicines

Published: October 07, 2025

Surgical technique of hepato-celiac lymphadenectomy in relapsed ovarian cancer.

Surgical technique of hepato-celiac lymphadenectomy in relapsed ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 15, 2025

Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis.

Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 13, 2025

Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial.

Optimal timing of primary debulking surgery in advanced ovarian cancer: insights from the TRUST trial.

Journal: Journal of gynecologic oncology

Published: August 04, 2025

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.

Journal: Innovation (Cambridge (Mass.))

Published: January 19, 2025

g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.

g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.

Journal: Chinese medical journal

Published: November 13, 2024

Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.

Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.

Journal: Nature medicine

Published: February 22, 2024

Shanghai Gynecologic Oncology Group's consensus on the academic and industry's clinical trial types.

Shanghai Gynecologic Oncology Group's consensus on the academic and industry's clinical trial types.

Journal: Chinese medical journal

Published: February 02, 2024

Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.

Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.

Journal: Science advances

Published: November 22, 2023

Showing 1-12 of 66

Last Updated: 09/26/2026